疏血通注射液对急性心肌梗死患者相关指标的影响

Effects of Shuxuetong Injection on Related Indexes of Patients with Acute Myocardial Infarction

目的:探讨疏血通注射液对急性心肌梗死(AMI)患者相关指标的影响。方法 :回顾性分析156例AMI患者资料,按治疗方案的不同分为对照组(65例)和观察组(91例)。对照组患者给予常规治疗;观察组患者在对照组治疗的基础上给予疏血通注射液6 mL,加入5%葡萄糖注射液250 mL中,静脉滴注,每日1次。两组均连续治疗5 d。观察两组患者的血管再通率、再通时间、再闭塞发生率,治疗前后左心室射血分数(LVEF)、活化部分凝血酶原时间(APTT)、凝血酶原时间(PT)、纤维蛋白原(FIB)水平,不良心血管事件发生情况及不良反应发生情况。结果:观察组患者血管再闭塞发生率、不良心血管事件总发生率均显著低于对照组,差异均有统计学意义(P<0.05);两组患者血管再通率、再通时间、不良反应发生率比较,差异均无统计学意义(P>0.05)。治疗后,两组患者LVEF、APTT、PT均显著高于同组治疗前,且观察组显著高于对照组;两组患者FIB显著低于同组治疗前,且观察组显著低于对照组,差异均有统计学意义(P<0.05)。结论 :在常规治疗的基础上,疏血通注射液可降低AMI患者的血管再闭塞发生率,改善心功能,减少不良心血管事件发生,且未增加不良反应的发生。

OBJECTIVE： To investigate the effects of Shuxuetong injection on related indexes of patients with acute myocardial infarction （AMI）. METHODS： The data of 156 AMI patients were analyzed retrospectively, and then divided into control group （65 cases） and observation group （91 cases） according to therapy plan. Control group received routine treatment. Observation group was additionally given Shuxuetong injection 6 mL added into 5% Glucose injection 250 mL intravenously, once a day, on the basis of control group. Both groups were given treatment for 5 d. The incidence of vascular recanalization, recanalization time, the incidence of reocclusion as well as LVEF, APTT, PT, FIB, the occurrence of adverse cardiovascular events before and after treatment as well as the occurrence of ADR were observed in 2 groups. RESULTS： The incidence of reocclusion and adverse cardio- vascular events in observation group was significantly lower than control group, with statistical significance （P〈0.05）. There was no statistical significance in the incidence of vascular recanalization, recanalization time or the incidence of ADR between 2 groups （P〉0.05）. After treatment, the levels of LVEF, APTT and PT in 2 groups were significantly higher than before treatment, and the observation group was significantly higher than the control group. The levels of FIB in 2 groups were significantly lower than be- fore treatment, and the observation group was significantly lower than the control group, with statistical significance （P〈0.05）. CONCLUSIONS ： Based on routine treatment, Shuxuetong injection can reduce the incidence of reocclusion, improve cardiac fimc- tion and reduce the incidence of adverse cardiovascular events without increasing the occurrence of ADR.